Bruce Strober, MD, PhD

In " Skin Clearance and PsA Prevention with Biologics in Psoriasis," Dr. Strober distills the discussion into practical guidance for the clinic.

"Reading the Risankizumab Claims Data: Protopathic Bias and Study Limitations" weighs what the data can and cannot support.

This episode, "Inside the Risankizumab and PsA Risk Study: Claims Data on Targeted Immunomodulator Therapies," examines the study design and the numbers behind it.

In "Can Psoriasis Treatment Prevent PsA? Biologics, Phototherapy, and Other Treatments," Dr. Strober takes up whether some psoriasis treatments do more than clear skin.

"Modern Psoriasis Treatment: From Topicals to IL-23 and IL-17 Biologics" steps back to survey how clinicians actually treat psoriasis in 2026.

Psoriatic arthritis often surfaces years after the skin diagnosis, making the dermatology visit a decisive checkpoint. This opening segment weighs risk markers and the structured questioning that surfaces joint disease before damage sets in.